Gathering the record
Relay is organizing the evidence and source boundaries.
Heterogeneous animal-derived peptide mixture
Cortexin is a mixture of low-molecular-weight peptides derived from animal cerebral cortex, not one defined peptide.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Cortexin is an animal-derived mixture of small peptides from cerebral cortex tissue, not one chemically defined peptide. It is marketed for neurologic uses in some countries but is not FDA approved.
Regional studies have explored stroke and chronic cerebral ischemia. Because Cortexin is a mixture, product standardization and the identity of any active component are fundamental evidence questions.
A 490-person randomized, blinded stroke study compared intravenous with intramuscular Cortexin, but both groups received the product, so it did not establish benefit versus placebo or standard care. Smaller regional reports describe neurologic outcomes with limited independent replication.
Which components are active, whether different products are comparable, whether benefits reproduce against an appropriate control, and how safety compares with established care remain unresolved. Mixture findings cannot be assigned to a single peptide.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A multicenter randomized, blinded study investigated two administration forms of Cortexin in adults with acute ischemic stroke and followed outcomes for ninety days.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Limited and regionally concentrated human evidence; mixture identity and independent replication remain important constraints.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Which components are active, whether results independently replicate across standardized formulations, and how benefit-risk compares with established care.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Both groups received Cortexin, so the study does not establish benefit versus placebo or standard care. The animal-derived mixture, regional setting, and lack of independent formulation-standardized replication limit transferability. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Randomized clinical reports exist, including stroke and chronic cerebral ischemia studies, but much of the literature is regionally concentrated and does not establish broad regulatory consensus.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Which components are active, whether results independently replicate across standardized formulations, and how benefit-risk compares with established care.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
Published clinical reports have studied branded Cortexin formulations in neurologic settings. Results apply to the tested mixture and design, not to an inferred active sequence or every product sold under the name.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter randomized double-blind active-form comparison
Adults with acute ischemic stroke
A 490-participant randomized double-blind study compared two administration forms over a 90-day follow-up.
Study administration: Cortexin intravenous versus intramuscular form
Limitations: Both groups received Cortexin; this does not establish benefit versus standard care or placebo.
Randomized comparative clinical study
Adults with chronic cerebral ischemia
Endpoints were not fully described in the current record.
A randomized dose-comparison report evaluated 10 mg and 20 mg regimens against a comparison group.
Study administration: Not stated in the current record.
Limitations: Regional publication, formulation-specific findings, and limited independent replication.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review summarizes a heterogeneous set of neurologic reports.
Study administration: Not stated in the current record.
Limitations: Review-level synthesis cannot resolve mixture standardization or study-quality limitations.
Safety snapshot
Trials report adverse events within their study windows, but heterogeneous sourcing and limited independent surveillance constrain uncommon-event assessment.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceTrials report adverse events within their study windows, but heterogeneous sourcing and limited independent surveillance constrain uncommon-event assessment.
Controlled human evidenceLow-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.
Open sourceNo source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryMarketed in some countries; not FDA-approved in the United States. Which components are active, whether results independently replicate across standardized formulations, and how benefit-risk compares with established care.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 41524350
PMID 30335070
PMID 24738258